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Introduction
Six to 7 million people are estimated to be infected by Trypanosoma cruzi, the parasite causing
Chagas disease [1]. Thirty to 40% of them, i.e., 1.8 to 2.4 million people, will suffer cardiac dis-
orders and/or digestive clinical manifestations if they are not treated early during the course of
the infection [1, 2]. However, only a small fraction of patients are properly diagnosed and
treated [3]. Current clinical guidelines recommend treating T. cruzi–infected people if they are
asymptomatic or present early symptoms of the disease (Table 1) [4, 5]. Benznidazole (BNZ)
and nifurtimox (NFX) are the first-line antiparasitic treatments currently available, both with
long administration regimens (60 days) that can produce adverse side effects [6–8]. Despite
the fact they are not 100% effective in patients with chronic disease [9–12], they are the only
drugs currently registered, and the benefits of their administration have been confirmed in
several clinical studies [9–14]. Currently, clinical trials with new compounds, using alternative
regimens that aim to maintain efficacy whilst reducing toxicity, are ongoing and could lead to
new therapeutic opportunities and/or policy change [15].
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In any case, the absence of a test for the early assessment of treatment efficacy, often called a
test of cure (ToC), is a major obstacle to Chagas disease control. Accurately monitoring treat-
ment response would undoubtedly improve patient management and support the conduct of
clinical trials. Although treatment efficacy and treatment response may be conceptually differ-
ent, we are using these terms synonymously for the purpose of the current target product pro-
file (TPP) [16, 17].
Unfortunately, there is no gold-standard test for the early determination of whether some-
one who has been treated for chronic Chagas disease has been cured or not. Current methods
used for monitoring Chagas disease treatment efficacy are suboptimal due to the fact that: (1)
clinical progression of the disease is silent and associated with complex and mostly unknown
host–pathogen interactions; (2) once in the chronic stage, infected subjects remain seropositive
for years, with very low and intermittent parasitemia counts; and (3) as a consequence, in the
chronic phase, parasitological detection methods have very low sensitivity, whereas molecular
detection can only be done in reference laboratories. Besides, clinical evaluation may not be
specific to Chagas disease and cannot be used in cases where some structural tissue damage
already exists. In addition, measuring seroconversion by conventional tests is not viable as it
may take years or decades for a patient with chronic disease to revert serologically. Finally, the
posttreatment detection of circulating parasites (through their DNA) by molecular amplifica-
tion techniques, such as quantitative polymerase chain reaction (qPCR), may be useful for
determining treatment failure, but a negative qPCR result cannot be considered a surrogate of
cure [18].
Development of a test that can determine in a timely manner if a patient treated for Chagas
disease has successfully responded to treatment has therefore been identified as a priority [16].
As mentioned above, such a test could be used in two different scenarios or use cases: (1) the
daily clinical management (DCM) of Chagas disease patients posttreatment to decide if and/or
when a patient should be followed up after treatment completion and (2) in the context of clin-
ical trials (CT), where the test would be used as the endpoint measurement for the evaluation
of new anti–T. cruzi treatments.
The development of this test (or tests) should be guided by a TPP. TPPs for a test to assess
treatment response in Chagas disease patients have been suggested previously [17, 19]. Build-
ing on them, we now present a TPP specifically describing the required technical and perfor-
mance characteristics of a test to determine if a Chagas disease patient has been cured
posttreatment. We have considered two use scenarios: day-to-day healthcare provision and
clinical evaluation of new anti–T. cruzi drugs or alternative regimens of the drugs currently
available.
Methods
As in previous TPPs [17, 19], we defined the test characteristics on the basis of Chagas disease
expert opinion on the response to anti–T. cruzi treatment in Chagas disease patients. Discus-
sions leading to this TPP document were coordinated and developed by the NHEPACHA
(new tools for the diagnosis and evaluation of Chagas disease patients) network [20]. Created
in 2011 with the goal of identifying and validating the use of biomarkers for Chagas disease,
the network currently consists of 14 groups, 11 of them from America and the remaining three
from Europe. The network includes expert clinicians working with patients, researchers work-
ing in academia, and specialists in industry and product development partnerships (PDPs).
All of them were first asked to come to a consensus on a series of definitions to be used in the
TPP (Table 1). Then they were asked to agree on the parameters for each of the test character-
istics. The categories used in the TPP were adapted from previously published TPPs for
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Table 1. Definitions used to develop the TPP for a test for the early assessment of treatment efficacy in Chagas disease patients.
Concept Definition Current diagnostic
Acute Chagas
disease
The first phase of T. cruzi infection is characterized by a high number of
parasites circulating in the blood that can be detected by direct methods
(e.g., microscopy). In most cases, symptoms are absent or mild and
unspecific. Acute Chagas disease occurs after a short incubation time (5–
15 days on average, longer for cases of transmission by blood
transfusion) and can last for 2 months. Infection may occur by vectorial
transmission when T. cruzi parasites enter the body via a skin break
caused by a bug bite, by skin breaching after scratching the bite site, or
via mucosal entry (e.g., oral transmission through contaminated food).
Vector-independent transmission routes include: congenital infection;
blood transfusion; cell, blood, or tissue transplantation; and needle
sharing. Infection can also occur accidentally after the manipulation of
infected triatomines and/or infected animals or laboratory samples.
Immunocompromised patients with chronic T. cruzi infection are at risk
of the disease being reactivated and then undergoing an acute
presentation with a high mortality rate.
During the acute phase, T. cruzi infection is diagnosed by direct
detection of the parasite or parasite DNA circulating in the
bloodstream or the detection of specific IgM and IgG antibodies.
Chronic Chagas
disease
After a variable period (4–8 months) of infection or after unsuccessful
treatment, the chronic phase is established during which T. cruzi
parasites mainly persist in a variety of tissues. Patients in the chronic
phase of the disease can be clinically divided into two groups:
•Asymptomatic patients without demonstrable disease, who are
characterized by the absence of damage or organ alterations following
evaluation through “classic” diagnostic tools (electrocardiogram, plain
thoracic X-rays, echocardiogram, Rezende technique). These patients’
clinical status is also known as the chronic indeterminate form.
•Symptomatic patients with demonstrable disease (around 30%–40%
of those chronically infected), who show a variable degree of cardiac
disorder and/or digestive clinical manifestations. They suffer from the
chronic determinate form.
Chronic Chagas disease patients can also be classified based on the level
of tissue damage (e.g., Kuschnir´s modified classification for cardiac
damage or Ximenes and Rezende classifications for digestive damage)
[24].
Patients in the chronic phase are diagnosed via the detection of T.
cruzi antibodies which, according to WHO recommendations, entails
obtaining concordant positivity in two tests based on different sets of
T. cruzi antigens [4].
Chagas disease
treatment
According to current guidelines [25], treatment should be offered to all
patients except those with advanced Chagas disease (e.g., Kuschnir grade
III), where it is not recommended.
• In patients with Kuschnir grade II, age can be taken into
consideration when evaluating treatment administration.
• Treatment of patients with digestive damage is dependent on the
degree of involvement, similar to the approach for cardiac patients (not
an evidence-based recommendation).
Arguments in favor of excluding advanced cases from treatment are
based on the rationale that in the late stages of the disease, parasite load
and activity may no longer be relevant in determining disease evolution.
This was concluded by the BENEFIT trial (ClinicalTrials.gov Identifier:
NCT00123916) in relation to cardiac pathology [12].
Cure in Chagas
disease patients
Elimination of T. cruzi parasites from the patient’s body following
treatment.
Treatment
efficacy
Treatment success: elimination of T. cruzi parasites from the patient’s
body, independently of whether the infection is asymptomatic or
symptomatic, after specific treatment.
Treatment failure: the detection of T. cruzi parasites in the patient’s body
after specific treatment.
Markers of T. cruzi elimination (treatment success):
• Indirect: seroconversion (from positive to negative) in terms of
reactivity against T. cruzi antigens.
Markers of T. cruzi presence (treatment failure):
• Direct: positive parasitemia measured by T. cruzi DNA
amplification reaction.
• Indirect: persistence of reactivity against T. cruzi antigens.
IgG, immunoglobulin G; IgM, immunoglobulin M; TPP, target product profile; WHO, World Health Organization
https://doi.org/10.1371/journal.pntd.0008035.t001
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diagnostic tests [21–23] and included specific features such as number of samples or timing of
sampling.
Several face-to-face meetings were organized (in March 2017, March 2018, and March
2019), and email surveys were sent around in preparation for the final consensus document.
For each of the characteristics in the TPP, specialists were asked to take into consideration
both use-case scenarios. Since the requirements for a test to be used as an endpoint in clinical
trials for new drugs or new regimens (use case 1; CT) may be more stringent, such a test should
meet, in general, “ideal” conditions. This does not apply to the “operational characteristics” in
which “ideal” conditions are related to a test to improve daily clinical management of treated
Chagas disease patients (use case 2; DCM).
Results
The TPP for a test for early assessment of treatment response in Chagas disease patients is pre-
sented in Table 2. This takes into consideration the following parameters: scope, performance,
and operational characteristics.
Discussion
A test allowing the early assessment of antiparasitic treatment efficacy in Chagas disease
patients has been recognized as a priority for a long time [16, 17, 19, 27]. However, despite
some recent advances [28, 29], these tests are currently only available for research use.
The development and evaluation of such a test is challenging for multiple reasons, including
the lack of a practical gold standard and consensus on the definition of a cure for Chagas dis-
ease patients (see Table 3). In this paper, we have tried to address these issues and built on the
previous TPPs [17, 19] to develop a detailed description of the requirements of a ToC for two
use cases: management of Chagas disease patients and development of new drugs or alternative
regimens using currently available drugs.
This TPP should guide the development of tests to rapidly evaluate Chagas disease antipara-
sitic treatment efficacy. These tests might be based on biomarkers derived from the parasite,
such as PFR2, KMP11, HSP70, the peptide 3973, F29, αGal-containing antigens, and the list of
epitope-based antigens provided by Granjon and colleagues [28–34]; biomarkers derived from
the host, such as hypercoagulability markers F1+2 and ETP [35], and the APOA1 and FN frag-
ments [36]; or a combination of both. At present, preliminary results using Infinity antigen 3
(AG 3; derived from the parasite) and the SaMi-Trop cohort from Brazil show promise, but
further insight is required to ensure that the 40% parasite clearance reported upon treatment
persists over time [28]. It also remains to be shown how this compares to trends in conven-
tional serology reactivity and whether similar levels of response can be found with samples
from other geographic origins [28]. All the studies that evaluated host-derived markers were
performed with a reduced number of samples, and therefore their potential will need to be
assessed with larger collections.
The TPP can also help to evaluate the approaches currently used to assess treatment effi-
cacy: serology and qPCR. The latter has been used in clinical studies as a test for treatment fail-
ure. Serial blood sampling and molecular amplification reactions have been implemented to
assess the absence of circulating T. cruzi DNA in chronically infected patients during treat-
ment follow-up [37]. A major limitation of the use of qPCR to monitor treatment response is
that it has not been assessed in long-term cohorts and studies; consequently, a negative molec-
ular outcome at a specific time cannot exclude that a relapse may occur later on. As a result,
there remains an urgent need for more reliable and straightforward tests to evaluate treatment
efficacy, which we expect this TPP can help to streamline.
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Table 2. TPP for a test for early assessment of treatment response in Chagas disease patients.
Characteristic Ideal Acceptable Comments
Scope
Goal of test or
intended use
To be used as an endpoint in CTs
evaluating new anti–T. cruzi treatments or
regimens.
To guide the management of Chagas disease
patients posttreatment.
Objective: Develop a test to determine if a
patient treated for Chagas disease has
successfully responded to treatment, which is
simple to perform and can be used as early as
possible.
Target population to be
tested • Treated patients in the acute phase of
infection (all types�).
• Treated patients in the chronic phase
of infection more than 1 year of age (all
clinical forms��).
Treated patients in the chronic phase of
infection >1 year of age, with an
indeterminate clinical form or early tissue
damage involvement (e.g., Kuschnir scale
grades 0–1).
�Congenital, oral, reactivation upon
immune-suppression, vector-transmitted.
�� Indeterminate, cardiac, digestive, and
cardio-digestive.
Level of implementation
in the healthcare system
Healthcare structures with low-
complexity laboratory facilities (i.e.,
equipped at most with an ELISA reader).
Healthcare structures (same level as where
treatment is provided) with middle-to-high
laboratory facilities (i.e., those with a quality-
control program installed).
Here, the ideal conditions for the test would
better suit the acceptable scenario (DCM
rather than CT). Clinical trials are well-
funded and rely on well-equipped facilities to
run the required tests, whereas in most
endemic settings it is common to have poorly
equipped facilities.
Intended end-users Healthcare workers with no laboratory
skills.
Healthcare workers with laboratory training. Here, the ideal conditions for the test would
better suit the acceptable scenario (DCM
rather than CT).
Performance
Diagnostic sensitivity (Se) Sensitivity equal or better than 95%, so
that the test should be able to detect more
than 95% of the patients in whom the
treatment was efficacious.
Sensitivity equal or better than 60%, so that
the test should be able to detect more than
60% of the patients in whom the treatment
was efficacious.
Sensitivity for Chagas disease therapeutic
efficacy (as defined above) means correctly
identifying subjects in whom the treatment
was efficacious.
The sensitivity threshold established for each
scenario should be included in the 95% CI.
Diagnostic specificity (Sp) 100% More than 90% Specificity for Chagas disease therapeutic
efficacy (as defined above) means correctly
identifying subjects who failed to respond to
the treatment, so that they can be managed
accordingly.
The specificity threshold established for each
scenario should be included in the 95% CI.
Geographic working
range
Pan–T. cruzi test. Test works in a particular region but not in
all.
Eco-epidemiological geographic differences
observed in Chagas disease are associated
with the distribution of DTUs. In the ideal
use-case scenario the test should be universal,
i.e., capable of detecting all human-infecting
lineages. In the acceptable use-case scenario,
the test should work in at least one of the
regions defined by Miles et al. [26].
Operational
characteristics
In this section the ideal conditions for the test
would suit the DCM scenario, whereas the
acceptable condition would better suit the CT
scenario.
Type of test Single biomarker-based test. Single or multiple biomarker-based test.
Type of analysis Qualitative. Semiquantitative or quantitative.
Format Easy-to-use rapid test (e.g., lateral-flow
immuno-chromatographic strip format).
Lab-based test (e.g. ELISA-type assay).
Reading system Visual—no instrument required. Electronic-reader device required. Portable
device preferred.
Manual preparation of
samples (steps needed
after obtaining sample)
Maximum one step; precise volume
control and timing may be required.
Several steps; precise volume control and
timing required.
(Continued)
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Table 2. (Continued)
Characteristic Ideal Acceptable Comments
Reagent integration and
storage
All reagents should be contained in a
single device.
Reagent distribution and storage without
cold chain.
External reagents may be needed and if
required, should be included in the test kit,
preferentially presented in a ready to mix,
ready to use format.
Reagents distribution and storage without
cold chain.
All reagents and/or components of the kit
must be available commercially.
Time to results (excluding
sample collection)
Less than 3 hours. Less than 24 hours.
Type of specimen Capillary whole blood (finger prick
sample), saliva, and/or urine.
Whole blood extracted by venous puncture. If blood samples are needed, finger prick
samples would be preferred to venous
extraction of blood. However, it must be
considered that volumes larger than 50 μL
will require venous puncture.
It must also be considered that tests involving
the use of sera will require a centrifugation
step to segregate it from other blood
components. This will require the availability
of a centrifuge, which might not be the case
in low-complexity laboratories.
Sample volume Maximum volume by finger prick for
rapid tests can be 50 μL.
Maximum volume: 5 ml in adults; 1 ml in
children.
Number of samples A maximum of two samples: one
pretreatment and one posttreatment.
A maximum of three samples: one
pretreatment and up to two posttreatment.
Timing of sampling (of
the first posttreatment
sample)
Sampling within 6 months of treatment. Sampling within 24 months of treatment.
Power requirements None (instrument free), minimal portable
equipment, or minimum requirements
(battery operated or electricity for a short
time).
Standard operating currents with built-in UPS
for utilization in locations with variable
power.
The fewer the infrastructure requirements
(i.e., power, water, skills), the more likely is
that this test can be adopted at lower levels,
such as in the community or in primary
healthcare facilities.
Maintenance No maintenance or minimum
maintenance required by technically
trained personnel or remote support.
Preventive maintenance once a year or after
running more than 1,000 samples; only simple
tools and minimal expertise required; include
maintenance alert. Mean time to failure of at
least 18 months.
A maintenance alert and records on duration
of use are essential to ensuring proper
functionality in settings where it is unlikely
that the device will always be handled by the
same person. It is essential that only simple
tools and minimal expertise are necessary to
carry out maintenance, given the number of
devices likely to be in use.
Calibration None required. Remote or autocalibration.
Operating temperature Between 5 and 50˚C at up to 90% relative
humidity.
Between 5 and 40˚C at up to 70% relative
humidity.
High environmental temperatures and high
relative humidity are often present in
countries where Chagas disease is endemic.
Operating altitude Any altitude (up to 5,000 m). Up to 4,000 m. Andean regions above 3,500 m are not highly
endemic for Chagas disease, but taking La
Paz as an example (3,640 m), the minimal
working altitude for the test should be
established at this height.
Additional supplies (not
included in the kit)
None. If required, supplies should be
included in the test kit in a ready to use
format.
If required, supplies should be easy to obtain,
and preferentially presented in a ready to use
format.
In the case of molecular biomarkers, the
inclusion of low-cost equipment for nucleic
acid extraction from collected samples should
be considered. Otherwise, the sensitivity of
the test might be compromised.
Internal quality control Internal full-process positive controls and
negative controls.
Internal full-process positive controls. In the
case of molecular methods, negative controls
would be also mandatory.
In addition to EQA.
(Continued)
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Conclusion
We have presented a new and complete TPP for the development of tests for the early assess-
ment of Chagas disease treatment efficacy. In the context of this neglected infectious disease,
this is mostly an underrepresented area of investigation, and the current lack of such tests
greatly hampers the management of patients and control of the disease.
Today, the large majority of the 6 to 7 million people infected by T. cruzi remain untreated
[3]. Recent advances in diagnostics (e.g., use of rapid diagnostic tests) [38] and treatment (e.g.,
a shorter course—two weeks instead of eight weeks—of BNZ), as well as the implementation
Table 2. (Continued)
Characteristic Ideal Acceptable Comments
Training and education
needs
Less than 5 days of training. Less than 6 weeks of training, laboratory
personnel (biochemists, microbiologists).
Low training and education needs are
desirable, but this will depend on the type of
test (e.g., rapid diagnostic tests may require
less training than laboratory-based assays).
An EQA to survey the process and training
should be included at least once a year.
CT, clinical trial; DCM, daily clinical management; DTU, discrete typing unit; ELISA, enzyme-linked immunosorbent assay; EQA, external quality assessment; TPP,
target product profile; UPS, uninterruptable power supply
https://doi.org/10.1371/journal.pntd.0008035.t002
Table 3. Challenges towards the development and evaluation of a test for the early assessment of treatment effi-
cacy in Chagas disease patients.
Challenge Description
Definition of cure We agreed on parasite elimination as a surrogate of cure (see also the
definition in Table 1). We acknowledged the difficulty to ensure that the
parasite has been completely eliminated from the patient´s body. Nonetheless,
assuming that it is the presence of the parasite that drives (1) the appearance of
pathogenic events, (2) relapsing episodes, (3) and a long-term steady state of
antiparasitic antibodies, then any future ToC must support such elimination.
At the same time, we could have been taken into consideration clinical
improvement, but this would have ignored a large proportion of chronically
infected asymptomatic people undergoing treatment. Moreover, evaluation of
clinical improvement requires another type of test that can unequivocally
show tissue damage due to Chagas disease and its improvement upon
treatment.
Lack of (applicable) gold standard The current standard to determine cure is serological reversion from positive
to negative in two conventional tests based on distinct antigen sets [4, 5]. With
this reference, variable cure rates of 8%–40% have been reported in adult
patients treated in the chronic stage who were followed for 10 to 20 years [13,
30]. However, this is impractical from any perspective, whether the daily
management of the disease or the performance of a clinical trial, because
average follow-up periods do not last that long.
Lack of well-characterized samples
from patients
There is a limited number of samples from Chagas disease patients that
include baseline and follow-up samples collected over decades; such samples
would accelerate the identification of new biomarkers and the evaluation of
tests to assess treatment efficacy. Availability to the scientific community of
these samples will be fundamental for the development of much awaited tests
for the early assessment of treatment response.
Quantitative test What constitutes a significant change in biomarker levels should be
determined, whether it be by serological evaluation of the immune response to
a parasite or host-derived antigen or the measurement of a molecular-based
readout.
ToC, test of cure
https://doi.org/10.1371/journal.pntd.0008035.t003
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of new access strategies and an increasing availability of drugs, will hopefully result in a rapid
increase in the number of patients treated in the next few years [15]. A test for the early assess-
ment of treatment efficacy will be fundamental to managing those patients, as well as to accel-
erating the evaluation of new drugs or regimens. The TPP described in this article can guide
the development and uptake of these tests.
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